Infection prevention products company Tristel (TSTL) has issued an “AGM Statement” commencing that it is “pleased to announce that the company has had another record first half and expects to hit, if not exceed, it's three-year target of 10%-15% revenue growth by 30 June 2025”. So what of a current approaching 4% lower share price response to 375p?
Infection prevention products manufacturer Tristel (TSTL) has announced results for its half-year ended 31st December 2022 emphasising “achieving 16% revenue growth and a 16-fold increase in EBITDA”. So what of the shares currently up to 330p, but still down from when I previously concluded bearishly a year ago?
Previously writing on 'infection prevention products' company Tristel (TSTL), in October with the shares down to around 500p I concluded that still the valuation suggested entry into the US at a vast value indeed is needed and to avoid / sell. With the shares having last closed at 417.5p, what of today-announced half year results?...








